Category Press Releases

Legend Biotech Showcases CAR-T Cell Therapy Leadership for Multiple Myeloma Patients at ASCO and EHA

Legend Biotech, a leading global cell therapy company, has announced the forthcoming presentation of new and updated data from its CARTITUDE clinical development program at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology…

Read MoreLegend Biotech Showcases CAR-T Cell Therapy Leadership for Multiple Myeloma Patients at ASCO and EHA

UCB Announces Publication in The Lancet of Phase 3 Bimekizumab▼ Trials for Moderate to Severe Hidradenitis Suppurativa

UCB, a leading global biopharmaceutical company, has announced the publication of results from the Phase 3 BE HEARD I and BE HEARD II trials in The Lancet. These trials evaluated the effectiveness and safety of bimekizumab, an inhibitor of IL-17A…

Read MoreUCB Announces Publication in The Lancet of Phase 3 Bimekizumab▼ Trials for Moderate to Severe Hidradenitis Suppurativa

BRUKINSA Data Presented at ASCO Highlights Distinctive Clinical Efficacy for CLL and SLL Treatment

A global oncology company today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4, 2024. These presentations underscore the efficacy and safety…

Read MoreBRUKINSA Data Presented at ASCO Highlights Distinctive Clinical Efficacy for CLL and SLL Treatment

Astellas and YASKAWA Partner to Forge a Cutting-Edge Cell Therapy Ecosystem Blending Pharmaceutical and Robotics Expertise

Today, Astellas announced the signing of a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA), marking the beginning of discussions toward creating an innovative cell therapy ecosystem. This collaboration aims to merge pharmaceutical and robotics technologies, potentially revolutionizing cell therapy…

Read MoreAstellas and YASKAWA Partner to Forge a Cutting-Edge Cell Therapy Ecosystem Blending Pharmaceutical and Robotics Expertise

AstraZeneca Announces $1.5 Billion Facility for Antibody Drug Conjugates (ADCs) Manufacturing in Singapore

AstraZeneca to Establish $1.5 Billion Antibody Drug Conjugates (ADCs) Manufacturing Facility in Singapore AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore, aimed at enhancing the global supply of its Antibody Drug Conjugates (ADCs). ADCs represent next-generation cancer…

Read MoreAstraZeneca Announces $1.5 Billion Facility for Antibody Drug Conjugates (ADCs) Manufacturing in Singapore

FDA Grants Breakthrough Status to Roche’s Inavolisib for Advanced HR+, HER2- Breast Cancer

Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant. This treatment is for adult patients with PIK3CA-mutated, hormone receptor-positive, human…

Read MoreFDA Grants Breakthrough Status to Roche’s Inavolisib for Advanced HR+, HER2- Breast Cancer

Upneeq® Clinches 2024 Shape Skin Award for ‘Best Lift’ in the Professional Treatment Category

RVL Pharmaceuticals has proudly announced that Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, its prescription eye drop, has received the esteemed 2024 Shape Skin Award from Shape Magazine. This prestigious recognition, naming Upneeq® as “Best for Lift” in the professional category,…

Read MoreUpneeq® Clinches 2024 Shape Skin Award for ‘Best Lift’ in the Professional Treatment Category

AbbVie Showcases New Data Supporting Premier Gastroenterology Portfolio at 2024 Digestive Disease Week

AbbVie (NYSE: ABBV) announced it will present 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, occurring May 18-21 in Washington, D.C., and virtually. “At DDW, AbbVie is presenting research demonstrating rapid symptom relief and notable improvements in…

Read MoreAbbVie Showcases New Data Supporting Premier Gastroenterology Portfolio at 2024 Digestive Disease Week

OmniAb Showcases xPloration® High-Throughput Single B-cell Screening Data at 20th Annual PEGS Boston Summit

OmniAb has announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, held at the Omni Hotel. Earlier today, the company presented an overview of xPloration, a high-throughput single B-cell screening platform enhanced…

Read MoreOmniAb Showcases xPloration® High-Throughput Single B-cell Screening Data at 20th Annual PEGS Boston Summit